New announcement. Learn more

Migraine in Aotearoa New Zealand 2022 survey insights

In 2022, we conducted an online survey of people with migraine in Aotearoa New Zealand

We received 579 responses. Following removal of incomplete responses and those unlikely to have migraine, we had 530 responses for analysis.

Aim of the survey

The aim of the survey was to collect data on:

  • Chronic migraine

  • Medication overuse

  • Types of acute and preventive medications used

  • Non-medication acute and preventive treatments used

  • Disability from migraine

  • Impact of migraine on work

  • Use of, access to and experience of health services

  • Experiences of stigma

  • What could be improved for people with migraine

Survey development and data collection

The survey was developed using existing questions, specifically the Migraine Identification test (ID-Migraine testTM), the Migraine Disability Assessment Scale (MIDAS), demographic questions used by Stats NZ and the Ministry of Health and qualitative (open-ended) questions. The survey questionnaire is available below.

The survey was available online from 22 August 2022 to 7 Oct 2022 via a link on the MFANZ website landing page. It was promoted through our social media channels and networks, including Health Navigator, Neurological Foundation, New Zealand Pain Society, and a large engineering firm through a staff newsletter. Media articles linking to the survey webpage included a primary care electronic newsletter, an article by an AUT journalist and a press release on Scoop. For more information about the survey, see our methodology report.

Key insights

Analysis of the data is underway. To date, we have used the survey results as a New Zealand evidence-base in our Emgality application to Pharmac, and written articles (see below) about key insights that the survey results are providing on migraine in New Zealand.

As we progress the analysis and work towards publishing and disseminating the results further, we'll continue to share key insights and articles on this page.